BioStock: PHI expands market potential with regenerative medicine opportunity
Phase Holographic Imaging’s sales have doubled in one year, according to the company’s annual report published this week. However, it generates even more confidence for the company because PHI now addresses the entire spectrum of the healthcare market, not just medical research. The company aims to become a welded link in the value chain of modern medicine in general and regenerative medicine in particular. To find out more, BioStock contacted the company’s CFO, Patrik Eschricht.
Read the full interview with Patrik Eschricht on biostock.se.